Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -0.01% is 100% above its 5-year average of -43.70%, near the high end of its 5-year range (-91.45%–-0.01%).
99.94% above its 12-month average of -18.05%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -1.17%.
RETURN ON ASSETS (ROA)
-0.01%
RETURN ON ASSETS (ROA) AVG TTM
-18.05%
RETURN ON ASSETS (ROA) AVG 3Y
-43.07%
RETURN ON ASSETS (ROA) AVG 5Y
-43.70%
RETURN ON ASSETS (ROA) AVG 10Y
-37.80%
RETURN ON ASSETS (ROA) AVG 15Y
-52.41%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+99.94%
CURRENT VS 3Y AVG
+99.98%
CURRENT VS 5Y AVG
+99.98%
CURRENT VS 10Y AVG
+99.97%
CURRENT VS 15Y AVG
+99.98%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-23.88%
median of 431 covered companies
CURRENT VS SECTOR MEDIAN
+99.96%
vs the sector median at left
Assembly Biosciences, Inc.
Market Cap
$450.64M
Return on Assets (ROA)
-0.01%
TTM Avg
-18.05%
3Y Avg
-43.07%
5Y Avg
-43.70%
Market Cap
$453.70M
Return on Assets (ROA)
-83.42%
TTM Avg
-53.06%
3Y Avg
-45.42%
5Y Avg
-42.54%
Market Cap
$447.43M
Return on Assets (ROA)
-35.10%
TTM Avg
-26.63%
3Y Avg
-37.28%
5Y Avg
-39.51%
Market Cap
$468.31M
Return on Assets (ROA)
4.30%
TTM Avg
13.65%
3Y Avg
19.24%
5Y Avg
21.45%
Market Cap
$471.57M
Return on Assets (ROA)
-3.31%
TTM Avg
-8.72%
3Y Avg
-14.01%
5Y Avg
-17.66%
Market Cap
$428.16M
Return on Assets (ROA)
-31.15%
TTM Avg
-77.61%
3Y Avg
-57.20%
5Y Avg
-46.24%
Market Cap
$478.54M
Return on Assets (ROA)
-22.99%
TTM Avg
-20.77%
3Y Avg
-18.00%
5Y Avg
-22.63%
Market Cap
$481.33M
Return on Assets (ROA)
1.38%
TTM Avg
-14.74%
3Y Avg
-19.98%
5Y Avg
-18.10%
Market Cap
$416.68M
Return on Assets (ROA)
-41.58%
TTM Avg
-23.89%
3Y Avg
-13.16%
5Y Avg
-19.94%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Assembly Biosciences, Inc. (ASMB) | $450.64M | -0.01% | -18.05% | -43.07% | -43.70% |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $453.70M | -83.42% | -53.06% | -45.42% | -42.54% |
| Capricor Therapeutics, Inc. (CAPR)vs › | $447.43M | -35.10% | -26.63% | -37.28% | -39.51% |
| NRC Health (NRC)vs › | $468.31M | 4.30% | 13.65% | 19.24% | 21.45% |
| Cerus Corporation (CERS)vs › | $471.57M | -3.31% | -8.72% | -14.01% | -17.66% |
| Editas Medicine, Inc. (EDIT)vs › | $428.16M | -31.15% | -77.61% | -57.20% | -46.24% |
| Contineum Therapeutics, Inc. (CTNM)vs › | $478.54M | -22.99% | -20.77% | -18.00% | -22.63% |
| Arvinas, Inc. (ARVN)vs › | $481.33M | 1.38% | -14.74% | -19.98% | -18.10% |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $416.68M | -41.58% | -23.89% | -13.16% | -19.94% |
| Carlsmed, Inc. (CARL)vs › | $415.93M | -30.75% | -34.79% | -68.11% | -68.11% |
ROA
-0.0%
ROE
-0.0%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -2.38% |
| 2024-12-31 | -33.71% |
| 2023-12-31 | -44.75% |
| 2022-12-31 | -91.45% |
| 2021-12-31 | -67.97% |
| 2020-12-31 | -21.94% |
| 2019-12-31 | -28.06% |
| 2018-12-31 | -33.86% |
| 2017-12-31 | -25.29% |
| 2016-12-31 | -45.11% |
| 2015-12-31 | -21.27% |
| 2014-12-31 | -33.40% |
| 2013-12-31 | -71.52% |
| 2012-12-31 | -120.60% |
| 2011-12-31 | -92.71% |
| 2010-12-31 | -104.61% |
| 2009-12-31 | -2730.40% |
| 2008-12-31 | -1009.48% |
